Topic

Brian Drapeau is founder, GxPFrame and a cell and gene therapy manufacturing and quality systems consultant.

Articles

Pharma's AI ROI gap isn't strategy or tech; it's the missing workforce qualification step every other regulated capability requires.

Pharma's AI ROI Problem Isn't a Tech Problem but a Qualification Problem

Partha Anbil is at the intersection of the Life Sciences industry and Management Consulting. He has over 30+ years of experience in Life Sciences. He is also a Life Sciences industry advisor at MIT, his alma mater. He held senior leadership roles at WNS, IBM, Booz & Company, Symphony, IQVIA, KPMG Consulting, and PWC. Mr. Anbil has consulted with and counseled Health and Life Sciences clients on structuring solutions to address strategic, operational, and organizational challenges. He is a diplomat/fellow at MIT CSAIL. He is a healthcare expert member of the World Economic Forum (WEF). He was a member of the IBM Industry Academy, a very selective group of professionals inducted into the academy by invitation only, the highest honor at IBM.

Deepak Manjarekar is a veteran Data & AI leader with over three decades of experience driving business transformation through data. As Head of Coforge's Global Data HBU, he leads the company's Data & AI growth strategy, building on leadership roles at Mphasis and KPIT, where he successfully scaled high-growth data businesses.

A phased playbook for moving life sciences data warehouses to a compliant, AI-ready cloud Lakehouse, balancing GxP rigor with faster insights.

From Warehouse to Lakehouse: A Life Sciences Playbook for Regulated, AI-Ready Data Modernization

Vice President – Business Development
LGM Pharma

Checking in at 2026's midyear mark, LGM Pharma's Mike Stenberg revisits his 2025 predictions on inspections, onshoring, GLP-1 delivery, and AI adoption.

From Predictions to Reality: Mike Stenberg Assesses Pharma Manufacturing's First Half of 2026

The future of compliant AI is not better content generation. It is better control over what happens next.

Can Governance-by-Design Make AI Compliant in Pharma? (Part II)

Associate Director, IT Applications
Hikma

Manish Garg takes a midyear look back at his 2026 predictions: AI's shift from speed to strategy, supply chain resilience, and why NDC-12 is the next DSCSA moment.

Midyear 2026 Check-In: AI, Supply Chains, and the NDC-12 Story Nobody's Watching

Arcana Life Sciences' Remco Munnik revisits his 2026 predictions on EU regulatory reform, AI adoption, and data governance, and previews pharma's biggest challenges for H2 2026.

Munnik Revisits His 2026 Predictions: A Midyear Check-In on Regulatory Reform, Data, and AI in Pharma

What pharma’s regulatory writers can borrow from clinical AI before the next inspection.

Don’t Make AI Smarter. Make It Traceable.

Patrick Lavery is an Editor for the MJH Life Sciences brands 

. Previously at MJH, he filled the same role for 

Videos

In the concluding segment of a multi-part interview, Jason Bryant of ArisGlobal explains how human-in-the-loop and human-on-the-loop are both still relevant in AI implementation in pharma.

HITL and HOTL: An Air Traffic Control Analogy for Agentic AI

ArisGlobal’s Jason Bryant continues a video supplement to his series of articles on the adoption and implementation of AI agents.

Full Autonomy Is a ‘No-Go Zone’: Setting Parameters for Agentic AI in Pharma

In an expansion of his written three-part series for PharmTech, Jason Bryant of ArisGlobal explains the interplay between autonomy and accountability that is essential for AI agents assisting the pharmaceutical industry.

Data and Artificial Intelligence